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Abstract
Background: Iron deficiency without anemia is related to adverse symptoms that can be relieved by
supplementation. Since a blood donation can induce such an iron deficiency, we investigated the clinical impact
of iron treatment after a blood donation.
Methods: One week after donation, we randomly assigned 154 female donors with iron deficiency without
anemia, aged below 50 years, to a four-week oral treatment of ferrous sulfate versus a placebo. The main outcome
was the change in the level of fatigue before and after the intervention. Aerobic capacity, mood disorder, quality
of life, compliance and adverse events were also evaluated. Hemoglobin and ferritin were used as biological
markers.
Results: The effect of the treatment from baseline to four weeks of iron treatment was an increase in hemoglobin
and ferritin levels to 5.2 g/L (P < 0.01) and 14.8 ng/mL (P < 0.01), respectively. No significant clinical effect was
observed for fatigue (-0.15 points, 95% confidence interval -0.9 points to 0.6 points, P = 0.697) or for other
outcomes. Compliance and interruption for side effects was similar in both groups. Additionally, blood donation
did not induce overt symptoms of fatigue in spite of the significant biological changes it produces.
Conclusions: These data are valuable as they enable us to conclude that donors with iron deficiency without
anemia after a blood donation would not clinically benefit from iron supplementation.
Trial Registration: ClinicalTrials.gov: NCT00981877
Background
Oral iron treatment in non-anemic iron-deficient sub-
jects can have beneficial effects on fatigue and physical
performance. The first evidence was provided 50 years
ago [1]. Further studies using fatigue questionnaires and
serum ferritin as a marker have confirmed this effect
[2-4]. Physiological measurements have also been carried
out in randomized double-blind controlled trials: aerobic
capacity increases [5-8] and muscle fatigability decreases
[9] among trained or untrained volunteers.
Iron deficiency without anemia (IDWA) is not a con-
traindication for blood donation, although highly preva-
lent among menstruating women. Studies show that 22%
of women of childbearing age have a ferritin level of less
than 15 ng/mL and 4% have iron deficiency anemia [10];
and between 6% and 27% of female blood donors eligible
for donation (that is, non-anemic) have iron deficiency,
depending on donation frequency [11]. A whole blood
donation of 450 mL contains around 55 g to 70 g of
hemoglobin and consequently 187 mg to 238 mg of iron.
This amount is between one and two thirds of the ideal
store for a woman, who could give blood three times a
year without any substitution, according to European
Council recommendations [12]. However, normal diet
does not compensate quickly enough for iron loss
through blood donations [13] and even a 16-week iron-
rich diet encouraged by professional counselors has only
a moderate effect on IDWA [14].* Correspondence: sophie.waldvogel@mavietonsang.ch
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Some authors advocate iron replacement after dona-
tion to prevent iron depletion, especially as donors
could be symptomatic [15-17]. According to an observa-
tional survey, fatigue is the most common systemic
adverse symptom which follows blood donation, affect-
ing 11% of female and 4% of male blood donors [18].
Recent prospective studies have proven that iron supple-
mentation versus a placebo allows donors to donate
more frequently, but did not consider the clinical benefit
for the donor [19-21]. Moreover, the design of these
studies could not distinguish between IDWA and iron
deficiency anemia after donation because, at the initia-
tion of iron replacement, only pre-donation values of
hemoglobin and ferritin were available. However, the
treatment of IDWA can have an impact on well-being
or work efficiency, as suggested in a non-randomized
controlled study [22].
The present study aimed to determine, in a randomized
controlled trial, the effect of iron treatment on fatigue
after blood donation among menstruating female blood
donors presenting with IDWA.
Methods
Design
This trial was a four-week, double-blind, placebo-con-
trolled, parallel group, randomized trial with a 1:1 allo-
cation ratio.
Physicians working at the Blood Transfusion Service
were responsible for seeing all potential participants
and controlling eligibility criteria. Once informed con-
sent forms were signed, a blood donation was per-
formed. Approximately 450 mL of venous blood was
collected within a blood pack set, allowing pre-dona-
tion sampling from which around 4 mL were used for
our study.
Setting
Donors coming for a whole blood donation at the Lau-
sanne Blood Transfusion Centre of the Swiss Red Cross
were recruited. Randomization and follow-up took place
at the Department of Ambulatory Care and Community
Medicine of Lausanne University Hospital.
Eligibility
Female donors aged 18 to 50 years and eligible for a
blood donation according to national regulations were
asked to participate. Exclusion criteria were psychiatric
conditions or diseases that rendered the participant
unable to give consent; thyroid, hepatic, rheumatic, kid-
ney, cardiopulmonary, or intestinal disease; acute or
chronic inflammation; diabetes; hemochromatosis; preg-
nancy; medical treatment that could alter iron absorp-
tion and any iron supplementation.
Intervention
Volunteers self-administered either 80 mg/day oral fer-
rous sulfate (FeSO4; Tardyferon, Robapharm, Boulogne,
France) or placebo for four weeks. To decrease side
effects, the pills could be taken during a meal; Verdon
et al. showed a significant decrease in fatigue without
drop-out for side effects using the same recommenda-
tion [4]. Iron pills were given in an electronic drug
monitoring system (Medication Event Monitoring Sys-
tem (MEMS), Aardex Europe, Switzerland [23]). The
iron treatment and placebo were identical in appearance
and taste.
Randomization, allocation, and concealment
Randomization took place a week after the blood donation
with the following criteria for inclusion: hemoglobin level
≥ 120 g/L, ferritin level ≤ 30 ng/mL. A simple random
allocation sequence without restriction was generated by
an independent pharmacy according to a pre-established
computer-generated list. Each drug package was identified
with a unique number according to the randomization
schedule and given to the nurse in charge of the partici-
pant. The code was held by the pharmacist and remained
unbroken until the end of the trial. The allocation
remained concealed from participants, care providers,
investigators and the statistician until the end of the statis-
tical analysis.
Outcomes
The primary outcome was the level of fatigue perceived
by donors, scored at baseline (randomization) and after
four weeks on a 10-point visual analogue scale (VAS)
ranging from ‘no fatigue’ (0) to ‘very severe fatigue’ (10).
A self-administered validated questionnaire evaluating
subjective fatigue with a Likert scale was also used - the
Fatigue Severity Scale (FSS) [24]. The score was obtained
by averaging responses from nine questions each ranging
from 1 to 7, increasing with the severity of fatigue. Both
fatigue scores were also measured just before donation.
Additional clinical outcomes were measured at baseline
and after treatment. Any change in aerobic capacity was
measured using a step test (Chester step test), which has
demonstrated excellent repeatability and a good correla-
tion with maximal oxygen uptake (r = 0.92) [25]. Depres-
sion and quality of life were assessed using the Prime-
MD [26] and the SF-12 [27] self-questionnaires,
respectively.
A blood count was measured from venous samples
exclusively, using an auto-analyzer (Sysmex XE 2100;
Sysmex Corporation, Kobe, Japan) and ferritin concentra-
tion was determined by an immunoturbidimetric assay
(Tina-quant; Roche Diagnostics, Mannheim, Germany),
from the first milliliter of the donation, one week after
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donation, and again after the intervention. To exclude
elevated ferritin levels caused by acute phase, C-reactive
protein was also measured at randomization. We stated
empirically that a value higher than 20 mg/L would be
considered as a significant inflammation, that is, an
exclusion criterion.
To explore bias related to menorrhagia, the pictorial
chart of Janssen et al. was used at randomization [28].
An electronic system (MEMS) recorded the date and
time each time the vial was opened. Subjects were asked
to use this electronic pill-bottle for each dose and to
swallow the dose immediately after opening. A study that
used this system has shown that compliance and motiva-
tion to take the treatment were thus improved [29].
Questions were asked at the end of the intervention to
evaluate whether the electronic device was properly used.
Unused pills were also counted. Medication adherence
was calculated as the number of days with at least one
opening of the electronic device divided by the total
number of monitored days. Finally, participants were
asked to guess to which group they had been assigned.
Statistical analysis
The main outcome variable was the level of fatigue at
four weeks. The sample size for randomized volunteers
was calculated using a two-sample comparison of means
to detect a one-point difference between the groups on
the VAS, similar to the minimal clinically appreciable dif-
ference for pain [30]. According to a previous study, a
standard deviation of two points was to be expected [4].
For a two-tailed test (a = 0.05, power = 0.80) and antici-
pating a 10% dropout rate, we calculated a total sample
size rounded to 140 participants.
Analyses were by intention-to-treat. The null hypoth-
esis was that there was no difference in fatigue VAS
scores between the experimental and control groups at
four weeks, adjusted for the baseline level of fatigue on
the same scale. Effects of treatment were measured using
linear regression, with fatigue levels at four weeks as the
dependent variables and group allocation and fatigue at
baseline as independent variables. The measures of effect
for the secondary outcomes were assessed by the same
method. A significant level of treatment effect was set at
P < 0.05, using a likelihood ratio test. Missing data from
dropouts were not replaced and only donors who were
followed-up after four weeks’ treatment were included in
the analysis. All calculations were performed with Stata-
Corp 2008, Statistical Software: Release 10.0, Stata Cor-
poration, College Station, Texas, USA.
Ethical considerations
The study was approved in July 2008 by the University
of Lausanne Ethics Committee for Clinical Research
(131/08) and the Swiss Agency for Therapeutic Products
(2008DR4328). Subjects presenting with anemia one
week after the donation were not randomized and
received 80 mg/day FeSO4 over three months. The pub-
lished protocol remains valid since no amendment was
necessary [31].
Results
Population characteristics
Between November 2008 and September 2010, 711
female donors were invited to participate. Of these, 154
donors presenting with IDWA were allocated to either
placebo or iron: 17 first-time donors and 137 consecutive
donors whose mean (range) number of donations was 8
(0 to 55). Reasons for non-eligibility, refusals and drop-
outs are provided in Figure 1. Randomization ensured
that the groups were similar at baseline for all measures
except for the pictorial bleeding test, where women from
the intervention group tended to have less menorrhagia
than those from the control group (Table 1). Nine
(12.2%) donors from the treatment group and four (5.6%)
from the placebo group reported amenorrhea. Figure 2
reports variations over time for both groups before and
after allocation. One week after the donation, we
observed a significant decrease in hemoglobin (mean =
-12.9 g/L, standard deviation (SD) = 6.5 g/L, P < 0.0001)
and serum ferritin (mean = -19.2 ng/mL, SD = 0.86, P <
0.0001) concentrations. A mean change in fatigue one
week after donation and before allocation was significant
but lower than one point on the FSS scale (mean = 0.27,
SD = 1.2, P = 0.0001), but not significant on the VAS
scale (mean = 0.17, SD = 2.6, P = 0.257).
Effects on outcomes
Iron supplementation had a significant effect on biologi-
cal markers but not on fatigue or aerobic capacity (Table
2). Complete outcome data were not available for nine
randomized donors; therefore full application of inten-
tion to treat was not possible. Nevertheless, results were
confirmed by worst and best case scenario analyses. An
absence of effect on the clinical outcome was confirmed
in a per-protocol analysis including 69 participants in
each group (confidence interval 95%, -0.71 to 0.74; P =
0.967). Effects on the physical condition score of the SF-
12 were mainly due to less interference of pain with nor-
mal work (P = 0.003), and less limitations in work or
other activities as a result of physical health (P = 0.012)
being reported in the FeSO4 group. The effect of treat-
ment on depression was inconclusive given the low num-
ber of donors with depression at four weeks (one in the
FeSO4 group versus two in the placebo group).
The proportion of donors whose hemoglobin concen-
tration returned to that recorded before blood donation
was similar in both groups (28.4% in FeSO4 versus 25.3%
in placebo; P = 0.711). On the other hand, 13 (18.3%)
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donors from the placebo group, and two (2.7%) from the
treatment group (P = 0.002) had lower hemoglobin con-
centrations four weeks after treatment than one week
after donation, three of which from the placebo group
became anemic (P = 0.115). Furthermore, after four
weeks of treatment, 2.7% of donors under FeSO4 had
blood concentrations of ferritin below 12 ng/m L com-
pared to 57.7% in the placebo group (P < 0.001). Mean
aerobic capacity increased both in the treatment group
(from 37.0 to 40.5 mLO2/kg/min; P = 0.0002), and in the
placebo group (from 36.9 to 40.1 mLO2/kg/min; P =
0.014).
Adverse events and adherence to treatment
No serious adverse event was reported. Undesirable
events mentioned included gastrointestinal symptoms (n
= 33), dizziness (n = 3), headache (n = 2), acne (n = 2),
palpitations (n = 1), and renal lithiasis (n = 1). The dif-
ferences between treatment and placebo are reported in
Table 3. Medication adherence was 96% and similar in
both groups. Seven participants interrupted their treat-
ment prematurely, two of which, one in each group, did
so because of a side effect.
Discussion
In this randomized double-blind controlled trial, a four-
week iron treatment of IDWA initiated one week after a
blood donation had no beneficial effect on fatigue and
consistently did not improve aerobic capacity, despite
having a significant impact on hemoglobin and ferritin
levels. Furthermore, a blood donation does not induce
significant fatigue measured one week after donation.
Figure 1 Flow chart.
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This study was sufficiently powered to exclude a clinically
significant effect of iron supplementation on fatigue.
Consequently, these data provide important information
on the well-being of donors: blind iron-supplementation
after donation is not justified even if it has been shown
that adverse events related to a blood donation penalize
blood supply [32]. Taking these data into consideration,
we have decided not to introduce iron replacement for
young female donors at our transfusion center, since no
clinical benefit has been documented. However, further
trials focusing on long-term iron deficiency or chronic
fatigue among donors could lead to a change in our
policy.
Most participants of this study were made iron defi-
cient by a single blood donation while all previous experi-
mental studies included participants with long-term
IDWA induced by a progressive imbalance between
intake and loss of iron [2-9]. Indeed, the median pre-
donation ferritin level of donors randomized in our study
(34 ng/mL) was above the threshold of an overt iron defi-
ciency (12 ng/mL to 15 ng/mL) [33] and IDWA was
induced by acute bleeding. Interestingly, our results sug-
gest a difference in clinical responses to short-term and
long-term IDWA. Such a rapid transition to IDWA pos-
sibly has no effect on non-erythroid compartments, such
as nervous tissue or muscle. In this context, our results
do not conflict with data from the recent non-controlled
trial that showed numerous clinical benefits of iron treat-
ment after donation, reducing fatigue, prostration, diffi-
culty in concentrating, headache, hair loss and nail
breakage [22]. Besides the methodological limits of this
study, donors treated with iron already had IDWA before
donation since their inclusion criterion was a pre-dona-
tion level of ferritin of < 10 ng/mL. These donors were
therefore more likely to have iron deficits in non-ery-
throid compartments before blood donation.
However, comparing only biological changes between
groups, significantly more donors in the placebo group
had a decreased ferritin (P < 0.001) and hemoglobin (P =
0.002) level during intervention. Consequently, we should
not neglect that iron treatment could prevent sympto-
matic deterioration of iron status related to further
donations.
The total quantity of elemental iron (2,200 mg) orally
administered to each participant in our study was set
according to iron loss from a donation. While this is
Table 1 Baselines characteristics.
FeSO4
a
n = 74
Placebo
n = 71
Differencea
Absolute values
Age, mean years (SD) 32.9 (8.4) 30.7 (8.8) 2.1
Number of previous donations per year, n (%)
None 26 (35.1%) 25 (35.2%) -0.1%
One 29 (39.2%) 31 (43.7%) -4.5%
Two 19 (25.7%) 15 (21.1%) 4.6%
Weight, mean kg (SD) 64.2 (10.7) 67.6 (13.3) -3.4
Pictorial Bleeding Assessment chart
Score > 185, n (%) 6 (8.2%) 9 (12.7%) -4.5%a
Before donation; mean (SD)
Visual analogue scale for fatigue 3.4 (2.4) 3.9 (2.6) -0.6
Fatigue severity scale 2.5 (1.1) 2.7 (1.2) -0.2
Hemoglobin, g/Lb 138 (6.3) 135 (7.5) 3
Ferritin, ng/mLb 36.3 (22.4) 34.1 (15.0) 2.2
One week after donation; mean (SD)
Visual analogue scale for fatigue 3.9 (2.3) 4.0 (2.4) -0.02
Fatigue severity scale 2.9 (1.3) 3.0 (1.4) -0.1
Vitality score (SF-12V2)c 53.1 (12.9) 55.9 (11.3) -2.8
Chester step test, mLO2/kg/min 37.0 (7.2) 36.9 (5.9) 0.1
Hemoglobin, g/L 126 (5.2) 126 (5.3) -0.02
Ferritin, ng/mL 15.3 (7.7) 14.8 (7.3) 0.4
C-reactive protein, mg/L 2.1 (2.9) 2.9 (3.5) 0.8
Depression (PHQ-9), n (%) 4 (5.4%) 4 (5.7%) -0.3%
Mental health (SF-12NL)
d 38.6 (4.4) 39.3 (5.3) -0.7
Physical condition (SF-12NL)
d 53.7 (4.2) 53.6 (4.2) 0.09
aClinically significant difference. P-values of differences were not calculated, since randomization and allocation ensured that any difference could only be due to
chance. bHemoglobin and ferritin values before donation were not available for two donors from the control group. cOne donor from the intervention group and
two from the control group did not answer the 10th question on the SF-12V2. dSF-12 was incomplete for three donors in each group. SD: standard deviation.
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certainly not sufficient to compensate for all occurrences
of IDWA, the main purpose of this study was to investi-
gate the clinical effect of iron deficiency induced by a sin-
gle blood donation. Overall mean changes of hemoglobin
(Δ 11 g/L) and ferritin (Δ 13 ng/mL) levels between base-
line and the end of the treatment were consistent with
expected values. Such a biological change, induced by a
comparable amount of elemental iron, was enough in
10
Before donation Beginning of treatment
(1 week)
End of treatment
(5 weeks)
Iron
Placebo
VA
S 
fo
r f
at
ig
ue
 (f
ro
m
 0
 to
 1
0,
 
ce
nt
im
et
er
)
A Fatigue; VAS scale
0
1
2
3
4
5
95% CI
B Fatigue; FSS score
FS
S 
sc
or
e 
(1
 to
 7
)
Before donation Beginning of treatment
(1 week)
End of treatment
(5 weeks)
Iron
Placebo
95% CI
Before donation Beginning of treatment
(1 week)
End of treatment
(5 weeks)
Iron
PlaceboH
em
og
lo
bi
n 
 (g
/L
)
C Hemoglobin
95% CI
Before donation Beginning of treatment
(1 week)
End of treatment
(5 weeks)
Iron
Placebo
Fe
rr
iti
n 
 (n
g/
m
L)
D Ferritin
95% CI
0
10
20
30
40
50
60
0
5
115
120
125
130
135
140
145
150
0
1
2
3
4
5
6
7
6
7
8
9
Figure 2 Variations over time in fatigue, hemoglobin and ferritin among randomized volunteers.
Table 2 Outcomes in iron and placebo groups after four weeks of treatment.
FeSO4 Placebo Treatment effect
a
n = 74
mean (SD)
n = 71
mean (SD)
Crude ITT group difference
Δ (95%CI)
Significance level
LR test
Adjusted effectb
Δ (CI95%)
Visual analogue scale fatigue 3.4 (2.4) 3.5 (2.5) -0.15 (-0.9 to 0.6) P = 0.697 -0.18 (-0.9 to 0.6)
Fatigue severity scalec 2.5 (1.3) 2.6 (1.5) -0.06 (-0.4 to 0.3) P = 0.760 -0.05 (-0.4 to 0.3)
Vitality item (SF-12V2)d 53.6 (12.7) 55.3 (12.3) -0.24 (-3.9 to 3.4) P = 0.897 -0.13 (-3.8 to 3.6)
Chester step test, mLO2/kg/min
c 40.5 (14.5) 40.1 (17.0) 0.28 (-4.5 to 5.1) P = 0.907 0.02 (-4.8 to 4.8)
Hemoglobin, g/L 135 (6.7) 130 (5.3) 5.2 (3.5 to 6.9) P < 0.001 5.3 (3.7 to 7.0)
Ferritin, ng/mL 28.0 (9.8) 12.9 (8.3) 14.8 (12.2 to 17.4) P < 0.001 15.1 (12.6 to 17.6)
Quality of life (SF-12NL)
e
Physical condition 54.8 (3.3) 52.4 (5.2) 2.4 (1.1 to 3.7) P < 0.001 2.4 (1.1 to 3.7)
Mental health 40.1 (4.8) 40.7 (4.8) -0.4 (-2.0 to 1.2) P = 0.590 -0.5 (-2.0 to 1.1)
aTreatment effect was measured using linear regression, with treatment group and baseline value of fatigue as independent variables. bWas adjusted for baseline
imbalance for menstrual bleeding. cData were missing for one donor from the control group. dTwo donors from the intervention group and four donors from the
control did not answer question 10 from the SF-12V2. eSF-12 was not completed by nine donors from the intervention group and three from the control. CI:
confidence interval; ITT: intention to treat analysis; LR: likelihood ratio.
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some previous randomized placebo controlled trials to
obtain a favorable impact on fatigue and endurance
[4-6,8,9]. The degree of hypoferritinemia could also be cri-
tical. Indeed Verdon et al. showed that the treatment
effect on fatigue depended on baseline ferritin levels and
was not quantitatively significant among subjects with a
ferritin level above 50 ng/mL [4]. However, even if the
cut-off level of ferritin used for inclusion in our study was
not severe (< 30 ng/mL), the mean ferritin value before
treatment was 15 ng/mL, which is comparable to other
randomized placebo controlled trials dealing with IDWA
and showing a clinical improvement after iron treatment
[3,5,6,9].
Blood donors come spontaneously to the donation cen-
ter and are then clinically selected by professionals as
being adequately healthy and fit to donate. Consequently,
symptoms of fatigue should not be very frequent, as nota-
bly observed with half of the donors reporting a level of
fatigue before donation of three or less on the VAS.
Moreover, blood donation did not induce clinically sig-
nificant fatigue [34] in our study and the minor differ-
ence detected reflected rather a regression toward the
mean due to a natural fluctuation of fatigue. Therefore,
treatment effect on fatigue was possibly absent merely
because no symptom was perceived before intervention.
Indeed, our randomized controlled trial had the particu-
larity to exclusively use biological inclusion criteria to
evaluate treatment effect on fatigue among subjects with
IDWA. Furthermore, a measurement of aerobic capacity,
which is probably more appropriate for healthy volun-
teers, did not show any significant treatment effect either,
thus strengthening our result on fatigue.
Our study suggests that oral FeSO4 administered to
donors with IDWA improves quality of life. Surprisingly,
this isolated effect is exclusively related to physical con-
dition. More precisely, the main item of significance
concerned pain. To our knowledge there are no studies
reporting a significant effect of iron treatment on pain
and no physiological basis can support the link between
iron treatment and pain. Consequently, despite its sig-
nificance, this result has been considered as spurious.
Our study showed significant side effects in the treat-
ment group. This significance resulted mainly from hard-
ening of stools (absolute difference: 13%, P < 0.01), which
could be considered rather as a slight discomfort. More-
over, despite this significant side effect, drop-out rate for
a side effect, adherence to treatment and correct guessing
of treatment group were similar for each group. Interest-
ingly, Bruner et al. showed no difference in side effects,
particularly concerning constipation, between treatment
and placebo, in spite of a higher daily dose of FeSO4 (260
mg of elemental iron daily) and a proportion of subjects
in the iron treatment group that correctly guessed their
group assignment (62%) similar to that of our trial [35].
According to other clinical trials lacking in a placebo,
constipation related to oral FeSO4 is the most frequent
adverse effect, ranging from 11% in a study comparing
intravenous versus oral iron among postpartum patients
[36] to 30% of new cases in a study testing an older popu-
lation (mean age 62 years) [37]. Among donors, this side
effect seems to occur less frequently: 3% to 13% [22,38].
Our significant result on these moderate side effects
adds, however, an argument against broad-based supple-
mentation after each donation.
Our study had several limitations. Firstly, outcomes of
this study were restricted to fatigue, physical perfor-
mance, mood disorder and quality of life but did not
include other consequences of IDWA that could affect
Table 3 Undesirable events, compliance, and blinding.
FeSO4
n = 74
Placebo
n = 71
Absolute difference Significance level
Fisher’s exact test
Undesirable events, n (%)
Hard stools 13 (17.6%) 3 (4.2%) 13.4% P = 0.015
Liquid stools 9 (12.2%) 3 (4.2%) 8.0% P = 0.130
Abdominal pain 7 (9.5%) 4 (5.6%) 3.9% P = 0.534
Nausea 2 (2.7%) 0 (0%) 2.7% P = 0.497
Any gastrointestinal 25 (33.8%) 8 (11.3%) 22.5% P = 0.001
Other events 6 (8.1%) 3 (4.2%) 3.9% P = 0.495
Any event 29 (39.2%) 11 (15.5%) 23.7% P = 0.002
Days with correct dosing (compliance)a
Mean (SD) 26.3 (3.9) 26.5 (2.8) -0.2 P = 0.624
Median (range) 27 (7 to 35) 27 (13 to 35) 0
Believed to have receivedb n (%)
FeSO4 44 (60.3%) 9 (12.9%) 37.4% P < 0.001
Placebo 13 (18.8%) 42 (60.0%) 41.2%
Does not know 16 (21.9%) 19 (27.1%) 5.2%
aThe container with remaining pills was not returned by two donors from the control group. bOne patient from the intervention group did not answer.
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the well-being of donors. Treatment of IDWA has been
shown to improve cognitive function in randomized con-
trolled trials [35,39]. Moreover, in a recently reported
prospective clinical trial among blood donors, restless
legs syndrome was frequent (18%) and iron treatment
after donation was effective [38]. Concerning hair loss,
evidence that iron treatment is beneficial is still lacking
[40], but data from Pittori et al. suggest the beneficial
impact of oral iron treatment [22]. Secondly, our study
revealed that anemia was a highly prevalent form of iron
deficiency (44%) after donation, which contrasts with
data obtained from a comparable cohort of menstruating
women in the general population [10]. Indeed, 121
donors were excluded from randomization because of
anemia and received a three-month iron treatment. No
follow-up data are available since the aim of our study
was exclusively to explore IDWA. Anemia one week after
a blood donation is not surprising since our national
recommendation for the hemoglobin threshold for such
a donation is 120 g/L. Female participants who became
anemic one week after donation were also observed in a
study by Rosvik et al., even in the iron-treatment group
(one week of oral iron, 100 mg/day) and in spite of an
older mean age (43.2 years; SD = 12.1) and a higher pre-
donation hemoglobin level (137 g/L; SD = 0.7) [21].
According to Fowler’s data, around 75% of donors return
to their initial hemoglobin level after eight weeks but the
other subjects need a longer recovery period of up to 15
weeks [41]. Anemia induced by a blood donation may be
causative of disabling symptoms and it would be fair to
explore this clinically. Thirdly, we cannot exclude that
clinical effect of treatment was not detected because fol-
low-up took place too early. Indeed, Pittori et al.
observed a significant decrease in fatigue after six months
of follow-up, but not after only two months [22].
Conclusions
This randomized controlled trial has shown no clinical
benefit of treating IDWA induced by a single blood
donation. Moreover, significant fatigue induced by a
blood donation has not been observed. This first clinical
information concerning iron deficiency among donors is
reassuring but strongly prompts further clinical trials,
extended to iron deficiency anemia after donation, to
ensure progress in the management of blood donors.
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